cancer – Page 3 – media

New Method Shows Real Time Drug-Target Engagement between Cancer Cells

A new technique allows scientists to measure how efficiently cancer drugs reach their targets inside the body in real time, differentiating cells that interact with the drug from those which do not.
- Source: ScienceDaily
- 748
- July 17, 2018
cancer Market Views Researches
Dual Therapy of Ibrutinib Plus Venetoclax Improves Results in MCL

Ibrutinib plus venetoclax (ABT-199) improves outcomes over standard therapy in patients with mantle-cell lymphoma (MCL) and a poor prognosis reports a new research in the New England Journal of Medicine.
- Source: MDLinx
- 746
- July 14, 2018
cancer mantle cell lymphoma Researches
Bristol-Myers Squibb’s Combo Drug gets FDA Approval

Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
- Source: FiercePharma
- 4,406
- July 13, 2018
Bristol-Myers Squibb cancer colorectal cancer New Approvals
Fitbit Charge HR – Assessment of Health Conditions in Cancer Patients

A study report published in Nature's Digital Medicine partner journal shows that the wearable monitor Fitbit Charge HR could assess the health condition of cancer patients and predict their adverse events.
- Source: MobiHealthNews
- 683
- July 12, 2018
cancer Company Insight mHealth wearables
Torque’s T cell ‘Backpacks’ Show Promising Results Against Solid Tumors

Gilead’s Yescarta and Novartis’ Kymriah garnered a lot of interest among T-cell therapies after producing high response rates in patients with lymphoma and leukemia. However, the same has not been true for this technology in cases of solid tumors. In this novel procedure, patients’ immune-boosting T cells are extracted and engineered to target and destroy cancer cells.
- Source: FierceBiotech
- 1,116
- July 11, 2018
cancer Researches T-cell therapies
China’s Drastic Reduction in Cancer Drug Price

The newly formed health insurance administration in China intend to deepen discounts on cancer drugs which were already on its National Reimbursement Drug List (NRDL) based on public bidding and procurement based on cancer therapies. In the meantime, officials will start enlisting negotiations for treatments which were not included on the coverage list.
- Source: FiercePharma
- 812
- July 11, 2018
cancer China pharmaceutical drugs Policies
Night Shifts could Potentially Increases the Risk of Breast Cancer

More than 2.5 million people work night-shifts. In 2007, the International Agency for Research on Cancer (IARC) reported that working shifts generally disturbs momentum classified as being “probably carcinogenic to humans”.
- Source: MedicalNewsBulletin
- 789
- July 2, 2018
breast cancer cancer Researches
NBE Therapeutics Receives $20 million in Series B by Novo Holdings

Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
- Source: FierceBiotech
- 657
- June 29, 2018
biotech cancer Company Insight
Array BioPharma gets FDA Approval for Melanoma Combo

The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
- Source: FiercePharma
- 595
- June 28, 2018
cancer Melanoma New Approvals
A Novel Drug Therapy to Treat Multiple Cancers

RET-driven cancers include medullary and papillary thyroid cancer, non-small cell lung cancer, colorectal and bile duct cancer, which have been very difficult to treat till date. Chemotherapy has been the only available treatment but leads to multiple side effects.
- Source: Med India
- 535
- June 28, 2018
cancer Researches thyroid

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.